John Beshai to Female
This is a "connection" page, showing publications John Beshai has written about Female.
Connection Strength
0.230
-
Drug-Induced QTc Prolongation. Am J Cardiol. 2017 01 15; 119(2):280-283.
Score: 0.027
-
Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol. 2014 May 01; 113(9):1556-60.
Score: 0.022
-
Effect of defibrillation threshold testing-induced ventricular fibrillation on renal function. J Interv Card Electrophysiol. 2013 Dec; 38(3):209-15.
Score: 0.022
-
Reply to the editor-out of service lead. Heart Rhythm. 2013 May; 10(5):e68-9.
Score: 0.021
-
Out-of-service lead: abnormal presentation at follow-up. Heart Rhythm. 2013 Jan; 10(1):144-6.
Score: 0.020
-
Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail. 2011 Nov; 13(11):1231-7.
Score: 0.019
-
Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007 Dec 13; 357(24):2461-71.
Score: 0.014
-
Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
Score: 0.008
-
Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction. Echocardiography. 2016 Sep; 33(9):1344-52.
Score: 0.007
-
Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. Heart. 2016 11 01; 102(21):1742-1749.
Score: 0.007
-
Long-Term Success of Irrigated Radiofrequency Catheter Ablation of Sustained Ventricular Tachycardia: Post-Approval THERMOCOOL VT Trial. J Am Coll Cardiol. 2016 Feb 16; 67(6):674-683.
Score: 0.006
-
Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging. 2016 Jan; 9(1):e003738.
Score: 0.006
-
Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart. 2015 Nov; 101(22):1800-6.
Score: 0.006
-
Impact of baseline PR interval on cardiac resynchronization therapy outcomes in patients with narrow QRS complexes: an analysis of the ReThinQ Trial. J Interv Card Electrophysiol. 2015 Aug; 43(2):145-9.
Score: 0.006
-
ICD lead parameters, performance, and adverse events following continuous-flow LVAD implantation. Pacing Clin Electrophysiol. 2014 Apr; 37(4):464-72.
Score: 0.005
-
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 2012 Sep; 14(9):1236-86.
Score: 0.005
-
2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm. 2012 Sep; 9(9):1524-76.
Score: 0.005
-
Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012 Sep; 23(9):925-9.
Score: 0.005
-
Oscillatory breathing and exercise gas exchange abnormalities prognosticate early mortality and morbidity in heart failure. J Am Coll Cardiol. 2010 Apr 27; 55(17):1814-23.
Score: 0.004
-
Initial experience using a radiofrequency powered transseptal needle. J Cardiovasc Electrophysiol. 2010 Apr; 21(4):423-7.
Score: 0.004
-
Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm. 2006 Aug; 3(8):881-6.
Score: 0.003
-
The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction. J Am Coll Cardiol. 2006 Apr 18; 47(8):1683-8.
Score: 0.003
-
Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol. 2006 Feb; 29(2):142-5.
Score: 0.003